Prognostic value of programmed cell death ligand-1 expression in ovarian cancer: an updated meta-analysis
To investigate the prognostic significance of programmed cell death ligand-1 (PD-L1) in ovarian cancer. PubMed, Embase, and Cochrane Library databases were searched to identify studies that examined the prognostic significance of immunohistochemically assessed PD-L1 expression in histologically conf...
Saved in:
| Published in | Obstetrics & gynecology science Vol. 63; no. 3; pp. 346 - 356 |
|---|---|
| Main Authors | , , |
| Format | Journal Article |
| Language | English |
| Published |
Korea (South)
Korean Society of Obstetrics and Gynecology; Korean Society of Contraception and Reproductive Health; Korean Society of Gynecologic Endocrinology; Korean Society of Gynecologic Endoscopy and Minimal Invasive Surgery; Korean Society of Maternal Fetal Medicine; Korean Society of Ultrasound in Obstetrics and Gynecology; Korean Urogynecologic Society
01.05.2020
Korean Society of Obstetrics and Gynecology 대한산부인과학회 |
| Subjects | |
| Online Access | Get full text |
| ISSN | 2287-8572 2287-8580 |
| DOI | 10.5468/ogs.2020.63.3.346 |
Cover
| Abstract | To investigate the prognostic significance of programmed cell death ligand-1 (PD-L1) in ovarian cancer.
PubMed, Embase, and Cochrane Library databases were searched to identify studies that examined the prognostic significance of immunohistochemically assessed PD-L1 expression in histologically confirmed ovarian cancer. Eleven studies on PD-L1 expression involving 1,296 patients with ovarian cancer were included in this meta-analysis. Pooled hazard ratios (HRs) with corresponding 95% confidence intervals (CIs) were analyzed. Relationship between PD-L1 expression, and overall survival (OS) or progression-free survival (PFS) among patients with ovarian cancer was assessed. Subgroup analysis was performed based on the race, histologic type, and tumor International Federation of Gynecology and Obstetrics stage to evaluate the source of heterogeneity. Begg's Funnel plot and Egger's linear test were used to evaluate publication bias. Random-effects model was implemented when significant between-study heterogeneity (I
>50%) was observed.
We found no correlation between PD-L1 expression, and OS (HR, 1.13; 95% CI, 0.95-1.36; I
=78%) or PFS (HR, 1.07; 95% CI, 0.88-1.30; I
=75%) in ovarian cancer. Subgroup analyses showed that higher PD-L1 expression was associated with poor OS in non-Asian patients with ovarian cancer (HR, 1.26; 95% CI, 1.07-1.481; I
=59%). We found that upregulated PD-L1 expression to be a positive predictor for OS in serous ovarian cancer (HR, 0.98; 95% CI, 0.76-1.26; I
=74%) and a negative predictor for OS in non-serous ovarian cancer (HR, 1.29; 95% CI, 1.03-1.61; I
=64%) Furthermore, high PD-L1 expression was found to be a negative predictor for PFS of patients with non-serous ovarian cancer (HR, 1.12; 95% CI, 0.96-1.29; I
=37%).
Our meta-analysis suggests that PD-L1 expression is not associated with patient risk for ovarian cancer. |
|---|---|
| AbstractList | To investigate the prognostic significance of programmed cell death ligand-1 (PD-L1) in ovarian cancer.OBJECTIVETo investigate the prognostic significance of programmed cell death ligand-1 (PD-L1) in ovarian cancer.PubMed, Embase, and Cochrane Library databases were searched to identify studies that examined the prognostic significance of immunohistochemically assessed PD-L1 expression in histologically confirmed ovarian cancer. Eleven studies on PD-L1 expression involving 1,296 patients with ovarian cancer were included in this meta-analysis. Pooled hazard ratios (HRs) with corresponding 95% confidence intervals (CIs) were analyzed. Relationship between PD-L1 expression, and overall survival (OS) or progression-free survival (PFS) among patients with ovarian cancer was assessed. Subgroup analysis was performed based on the race, histologic type, and tumor International Federation of Gynecology and Obstetrics stage to evaluate the source of heterogeneity. Begg's Funnel plot and Egger's linear test were used to evaluate publication bias. Random-effects model was implemented when significant between-study heterogeneity (I2>50%) was observed.METHODSPubMed, Embase, and Cochrane Library databases were searched to identify studies that examined the prognostic significance of immunohistochemically assessed PD-L1 expression in histologically confirmed ovarian cancer. Eleven studies on PD-L1 expression involving 1,296 patients with ovarian cancer were included in this meta-analysis. Pooled hazard ratios (HRs) with corresponding 95% confidence intervals (CIs) were analyzed. Relationship between PD-L1 expression, and overall survival (OS) or progression-free survival (PFS) among patients with ovarian cancer was assessed. Subgroup analysis was performed based on the race, histologic type, and tumor International Federation of Gynecology and Obstetrics stage to evaluate the source of heterogeneity. Begg's Funnel plot and Egger's linear test were used to evaluate publication bias. Random-effects model was implemented when significant between-study heterogeneity (I2>50%) was observed.We found no correlation between PD-L1 expression, and OS (HR, 1.13; 95% CI, 0.95-1.36; I2=78%) or PFS (HR, 1.07; 95% CI, 0.88-1.30; I2=75%) in ovarian cancer. Subgroup analyses showed that higher PD-L1 expression was associated with poor OS in non-Asian patients with ovarian cancer (HR, 1.26; 95% CI, 1.07-1.481; I2=59%). We found that upregulated PD-L1 expression to be a positive predictor for OS in serous ovarian cancer (HR, 0.98; 95% CI, 0.76-1.26; I2=74%) and a negative predictor for OS in non-serous ovarian cancer (HR, 1.29; 95% CI, 1.03-1.61; I2=64%) Furthermore, high PD-L1 expression was found to be a negative predictor for PFS of patients with non-serous ovarian cancer (HR, 1.12; 95% CI, 0.96-1.29; I2=37%).RESULTSWe found no correlation between PD-L1 expression, and OS (HR, 1.13; 95% CI, 0.95-1.36; I2=78%) or PFS (HR, 1.07; 95% CI, 0.88-1.30; I2=75%) in ovarian cancer. Subgroup analyses showed that higher PD-L1 expression was associated with poor OS in non-Asian patients with ovarian cancer (HR, 1.26; 95% CI, 1.07-1.481; I2=59%). We found that upregulated PD-L1 expression to be a positive predictor for OS in serous ovarian cancer (HR, 0.98; 95% CI, 0.76-1.26; I2=74%) and a negative predictor for OS in non-serous ovarian cancer (HR, 1.29; 95% CI, 1.03-1.61; I2=64%) Furthermore, high PD-L1 expression was found to be a negative predictor for PFS of patients with non-serous ovarian cancer (HR, 1.12; 95% CI, 0.96-1.29; I2=37%).Our meta-analysis suggests that PD-L1 expression is not associated with patient risk for ovarian cancer.CONCLUSIONOur meta-analysis suggests that PD-L1 expression is not associated with patient risk for ovarian cancer. To investigate the prognostic significance of programmed cell death ligand-1 (PD-L1) in ovarian cancer. PubMed, Embase, and Cochrane Library databases were searched to identify studies that examined the prognostic significance of immunohistochemically assessed PD-L1 expression in histologically confirmed ovarian cancer. Eleven studies on PD-L1 expression involving 1,296 patients with ovarian cancer were included in this meta-analysis. Pooled hazard ratios (HRs) with corresponding 95% confidence intervals (CIs) were analyzed. Relationship between PD-L1 expression, and overall survival (OS) or progression-free survival (PFS) among patients with ovarian cancer was assessed. Subgroup analysis was performed based on the race, histologic type, and tumor International Federation of Gynecology and Obstetrics stage to evaluate the source of heterogeneity. Begg's Funnel plot and Egger's linear test were used to evaluate publication bias. Random-effects model was implemented when significant between-study heterogeneity (I >50%) was observed. We found no correlation between PD-L1 expression, and OS (HR, 1.13; 95% CI, 0.95-1.36; I =78%) or PFS (HR, 1.07; 95% CI, 0.88-1.30; I =75%) in ovarian cancer. Subgroup analyses showed that higher PD-L1 expression was associated with poor OS in non-Asian patients with ovarian cancer (HR, 1.26; 95% CI, 1.07-1.481; I =59%). We found that upregulated PD-L1 expression to be a positive predictor for OS in serous ovarian cancer (HR, 0.98; 95% CI, 0.76-1.26; I =74%) and a negative predictor for OS in non-serous ovarian cancer (HR, 1.29; 95% CI, 1.03-1.61; I =64%) Furthermore, high PD-L1 expression was found to be a negative predictor for PFS of patients with non-serous ovarian cancer (HR, 1.12; 95% CI, 0.96-1.29; I =37%). Our meta-analysis suggests that PD-L1 expression is not associated with patient risk for ovarian cancer. ObjectiveTo investigate the prognostic significance of programmed cell death ligand-1 (PD-L1) in ovarian cancer. MethodsPubMed, Embase, and Cochrane Library databases were searched to identify studies that examined the prognosticsignificance of immunohistochemically assessed PD-L1 expression in histologically confirmed ovarian cancer. Elevenstudies on PD-L1 expression involving 1,296 patients with ovarian cancer were included in this meta-analysis. Pooledhazard ratios (HRs) with corresponding 95% confidence intervals (CIs) were analyzed. Relationship between PDL1expression, and overall survival (OS) or progression-free survival (PFS) among patients with ovarian cancer wasassessed. Subgroup analysis was performed based on the race, histologic type, and tumor International Federation ofGynecology and Obstetrics stage to evaluate the source of heterogeneity. Begg’s Funnel plot and Egger’s linear testwere used to evaluate publication bias. Random-effects model was implemented when significant between-studyheterogeneity (I2>50%) was observed. ResultsWe found no correlation between PD-L1 expression, and OS (HR, 1.13; 95% CI, 0.95–1.36; I2=78%) or PFS (HR, 1.07;95% CI, 0.88–1.30; I2=75%) in ovarian cancer. Subgroup analyses showed that higher PD-L1 expression was associatedwith poor OS in non-Asian patients with ovarian cancer (HR, 1.26; 95% CI, 1.07–1.481; I2=59%). We found thatupregulated PD-L1 expression to be a positive predictor for OS in serous ovarian cancer (HR, 0.98; 95% CI, 0.76–1.26; I2=74%) and a negative predictor for OS in non-serous ovarian cancer (HR, 1.29; 95% CI, 1.03–1.61; I2=64%)Furthermore, high PD-L1 expression was found to be a negative predictor for PFS of patients with non-serous ovariancancer (HR, 1.12; 95% CI, 0.96–1.29; I2=37%). ConclusionOur meta-analysis suggests that PD-L1 expression is not associated with patient risk for ovarian cancer. KCI Citation Count: 0 ObjectiveTo investigate the prognostic significance of programmed cell death ligand-1 (PD-L1) in ovarian cancer.MethodsPubMed, Embase, and Cochrane Library databases were searched to identify studies that examined the prognostic significance of immunohistochemically assessed PD-L1 expression in histologically confirmed ovarian cancer. Eleven studies on PD-L1 expression involving 1,296 patients with ovarian cancer were included in this meta-analysis. Pooled hazard ratios (HRs) with corresponding 95% confidence intervals (CIs) were analyzed. Relationship between PD-L1 expression, and overall survival (OS) or progression-free survival (PFS) among patients with ovarian cancer was assessed. Subgroup analysis was performed based on the race, histologic type, and tumor International Federation of Gynecology and Obstetrics stage to evaluate the source of heterogeneity. Begg's Funnel plot and Egger's linear test were used to evaluate publication bias. Random-effects model was implemented when significant between-study heterogeneity (I2>50%) was observed.ResultsWe found no correlation between PD-L1 expression, and OS (HR, 1.13; 95% CI, 0.95–1.36; I2=78%) or PFS (HR, 1.07; 95% CI, 0.88–1.30; I2=75%) in ovarian cancer. Subgroup analyses showed that higher PD-L1 expression was associated with poor OS in non-Asian patients with ovarian cancer (HR, 1.26; 95% CI, 1.07–1.481; I2=59%). We found that upregulated PD-L1 expression to be a positive predictor for OS in serous ovarian cancer (HR, 0.98; 95% CI, 0.76–1.26; I2=74%) and a negative predictor for OS in non-serous ovarian cancer (HR, 1.29; 95% CI, 1.03–1.61; I2=64%) Furthermore, high PD-L1 expression was found to be a negative predictor for PFS of patients with non-serous ovarian cancer (HR, 1.12; 95% CI, 0.96–1.29; I2=37%).ConclusionOur meta-analysis suggests that PD-L1 expression is not associated with patient risk for ovarian cancer. |
| Author | Piao, Jinlan Lee, Maria Lim, Hyun Ji |
| AuthorAffiliation | 2 Department of Obstetrics and Gynecology, Seoul National University Hospital, Seoul, Korea 1 Department of Obstetrics and Gynecology, Seoul National University College of Medicine, Seoul, Korea |
| AuthorAffiliation_xml | – name: 2 Department of Obstetrics and Gynecology, Seoul National University Hospital, Seoul, Korea – name: 1 Department of Obstetrics and Gynecology, Seoul National University College of Medicine, Seoul, Korea |
| Author_xml | – sequence: 1 givenname: Jinlan surname: Piao fullname: Piao, Jinlan – sequence: 2 givenname: Hyun Ji surname: Lim fullname: Lim, Hyun Ji – sequence: 3 givenname: Maria surname: Lee fullname: Lee, Maria |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/32489980$$D View this record in MEDLINE/PubMed https://www.kci.go.kr/kciportal/ci/sereArticleSearch/ciSereArtiView.kci?sereArticleSearchBean.artiId=ART002586939$$DAccess content in National Research Foundation of Korea (NRF) |
| BookMark | eNp1Uk1v1DAQjVARLaU_gAvyEQ5ZnPFHbA5IVcXHSpVAqJytieNs3WbtxU5W9N_j3W0rioTnMKPxe2_smXlZHYUYXFW9buhCcKnex1VeAAW6kGxRjMtn1QmAamslFD16jFs4rs5yvqHlKNEoxV9Uxwy40lrRk8p_T3EVYp68JVscZ0fiQDYll3C9dj2xbhxJ73C6JqNfYejrhrjfm-Ry9jEQH0jcYvIYiMVgXfpASjhvepwKee0mrDHgeJd9flU9H3DM7uzen1Y_P3-6uvhaX377srw4v6wt13qqe61ASOhF-aTgwBtodON6Jhh1CE6A5JSpoXcd7RXtuGtFh4O0HQyttdax0-rdQTekwdxabyL6vV9Fc5vM-Y-rpdEgGShZsMsDto94YzbJrzHd7Qn7REwrg6m0ZnTGClBIUVLVKd5rrcG2ICUIPXSS665ofTxobeaudM66MCUcn4g-vQn-urxpa1pgjWZtEXh7L5Dir9nlyax93vUfg4tzNsCpbjRlwAr0zd-1Hos8zLUA2gPApphzcoOxfsKpjKyU9qNpqNktkSlLZHZLZCQzxfiuJc0_zAfx_3P-AOSKyr0 |
| CitedBy_id | crossref_primary_10_1016_j_critrevonc_2023_104084 crossref_primary_10_4081_ejh_2021_3185 crossref_primary_10_3390_diagnostics13203258 crossref_primary_10_3390_cancers13081972 crossref_primary_10_1186_s12885_023_10911_5 crossref_primary_10_21518_2079_701X_2021_9_76_86 crossref_primary_10_1007_s40944_022_00658_5 crossref_primary_10_1016_j_clinsp_2023_100204 crossref_primary_10_3389_fonc_2021_689829 crossref_primary_10_5937_smclk4_46109 crossref_primary_10_1007_s12094_024_03613_2 crossref_primary_10_1097_PPO_0000000000000557 |
| Cites_doi | 10.1007/s10549-014-3061-0 10.1158/1078-0432.CCR-16-2366 10.18632/oncotarget.6429 10.1016/j.cell.2015.03.030 10.1186/1479-5876-12-151 10.1016/S0140-6736(13)62146-7 10.21037/tcr.2017.02.29 10.1111/ejh.12228 10.1016/j.intimp.2017.08.017 10.1097/JTO.0000000000000500 10.1007/s12282-017-0781-0 10.1097/MD.0000000000012858 10.1186/s13048-017-0304-9 10.3389/fphar.2017.00561 10.1016/j.ygyno.2018.08.023 10.1038/nrc3239 10.1126/scitranslmed.3003689 10.5858/arpa.2016-0361-RA 10.1093/annonc/mdw625 10.1016/j.celrep.2017.07.075 10.3322/caac.21262 10.3802/jgo.2017.28.e77 10.1073/pnas.0406351101 10.1016/j.cell.2015.08.052 10.1038/bjc.2015.101 10.1073/pnas.0611533104 10.1097/PGP.0000000000000494 10.1016/j.lungcan.2016.05.001 10.1186/s13048-018-0414-z 10.1038/modpathol.2016.221 10.4143/crt.2016.066 10.1126/scitranslmed.aad7118 10.1007/s10147-016-0968-y 10.1016/j.ygyno.2016.03.008 10.1155/2018/9485285 |
| ContentType | Journal Article |
| Copyright | Copyright © 2020 Korean Society of Obstetrics and Gynecology. Copyright © 2020 Korean Society of Obstetrics and Gynecology 2020 Korean Society of Obstetrics and Gynecology |
| Copyright_xml | – notice: Copyright © 2020 Korean Society of Obstetrics and Gynecology. – notice: Copyright © 2020 Korean Society of Obstetrics and Gynecology 2020 Korean Society of Obstetrics and Gynecology |
| DBID | AAYXX CITATION NPM 7X8 5PM DOA ACYCR |
| DOI | 10.5468/ogs.2020.63.3.346 |
| DatabaseName | CrossRef PubMed MEDLINE - Academic PubMed Central (Full Participant titles) DOAJ : Directory of Open Access Journals [open access] Korean Citation Index |
| DatabaseTitle | CrossRef PubMed MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic PubMed |
| Database_xml | – sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 2287-8580 |
| EndPage | 356 |
| ExternalDocumentID | oai_kci_go_kr_ARTI_9263286 oai_doaj_org_article_c528a0a608b84d9992c7266259fb649b PMC7231937 32489980 10_5468_ogs_2020_63_3_346 |
| Genre | Journal Article |
| GrantInformation_xml | – fundername: ; grantid: 03–2019-0260 |
| GroupedDBID | 5-W 8JR 8XY AAYXX ACYCR ADBBV ALMA_UNASSIGNED_HOLDINGS AOIJS BAWUL BCNDV CITATION DIK EF. GROUPED_DOAJ HYE HZB KQ8 M48 PGMZT RPM ADRAZ NPM 7X8 5PM |
| ID | FETCH-LOGICAL-c499t-d982562d5546542412191ed3530ea2e5264038fdeb0d80b4e75baf6cb2f7ccce3 |
| IEDL.DBID | M48 |
| ISSN | 2287-8572 |
| IngestDate | Tue Nov 21 21:06:18 EST 2023 Wed Aug 27 01:21:58 EDT 2025 Thu Aug 21 18:34:08 EDT 2025 Fri Jul 11 07:34:21 EDT 2025 Thu Jan 02 22:54:28 EST 2025 Thu Apr 24 22:51:08 EDT 2025 Tue Jul 01 01:11:20 EDT 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 3 |
| Keywords | PD-L1 Prognosis Survival rate Progression-free survival Ovarian cancer |
| Language | English |
| License | Copyright © 2020 Korean Society of Obstetrics and Gynecology. Articles published in Obstet Gynecol Sci are open-access, distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c499t-d982562d5546542412191ed3530ea2e5264038fdeb0d80b4e75baf6cb2f7ccce3 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 https://ogscience.org/ |
| ORCID | 0000-0002-8017-3176 |
| OpenAccessLink | http://journals.scholarsportal.info/openUrl.xqy?doi=10.5468/ogs.2020.63.3.346 |
| PMID | 32489980 |
| PQID | 2409190323 |
| PQPubID | 23479 |
| PageCount | 11 |
| ParticipantIDs | nrf_kci_oai_kci_go_kr_ARTI_9263286 doaj_primary_oai_doaj_org_article_c528a0a608b84d9992c7266259fb649b pubmedcentral_primary_oai_pubmedcentral_nih_gov_7231937 proquest_miscellaneous_2409190323 pubmed_primary_32489980 crossref_citationtrail_10_5468_ogs_2020_63_3_346 crossref_primary_10_5468_ogs_2020_63_3_346 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 2020-05-01 |
| PublicationDateYYYYMMDD | 2020-05-01 |
| PublicationDate_xml | – month: 05 year: 2020 text: 2020-05-01 day: 01 |
| PublicationDecade | 2020 |
| PublicationPlace | Korea (South) |
| PublicationPlace_xml | – name: Korea (South) |
| PublicationTitle | Obstetrics & gynecology science |
| PublicationTitleAlternate | Obstet Gynecol Sci |
| PublicationYear | 2020 |
| Publisher | Korean Society of Obstetrics and Gynecology; Korean Society of Contraception and Reproductive Health; Korean Society of Gynecologic Endocrinology; Korean Society of Gynecologic Endoscopy and Minimal Invasive Surgery; Korean Society of Maternal Fetal Medicine; Korean Society of Ultrasound in Obstetrics and Gynecology; Korean Urogynecologic Society Korean Society of Obstetrics and Gynecology 대한산부인과학회 |
| Publisher_xml | – name: Korean Society of Obstetrics and Gynecology; Korean Society of Contraception and Reproductive Health; Korean Society of Gynecologic Endocrinology; Korean Society of Gynecologic Endoscopy and Minimal Invasive Surgery; Korean Society of Maternal Fetal Medicine; Korean Society of Ultrasound in Obstetrics and Gynecology; Korean Urogynecologic Society – name: Korean Society of Obstetrics and Gynecology – name: 대한산부인과학회 |
| References | ref13 ref35 ref12 ref34 ref15 ref37 ref14 ref31 ref30 ref11 ref33 Yoon (ref36) 2017 ref10 ref32 ref2 ref1 ref17 ref16 ref19 ref18 Mills (ref6) 2018 ref24 ref23 ref26 ref25 ref20 ref22 ref21 ref28 ref27 ref29 ref8 ref7 ref9 ref4 ref3 ref5 |
| References_xml | – ident: ref37 doi: 10.1007/s10549-014-3061-0 – ident: ref16 doi: 10.1158/1078-0432.CCR-16-2366 – ident: ref14 doi: 10.18632/oncotarget.6429 – ident: ref19 doi: 10.1016/j.cell.2015.03.030 – ident: ref24 doi: 10.1186/1479-5876-12-151 – start-page: 437 volume-title: Characterization of the immune microenvironment of high grade serous ovarian carcinomas in African American women: a study of 112 cases from the African American cancer epidemiology study (AACES) year: 2018 ident: ref6 – ident: ref2 doi: 10.1016/S0140-6736(13)62146-7 – ident: ref35 doi: 10.21037/tcr.2017.02.29 – ident: ref25 doi: 10.1111/ejh.12228 – ident: ref11 doi: 10.1016/j.intimp.2017.08.017 – ident: ref22 doi: 10.1097/JTO.0000000000000500 – ident: ref29 doi: 10.1007/s12282-017-0781-0 – ident: ref7 doi: 10.1097/MD.0000000000012858 – ident: ref8 doi: 10.1186/s13048-017-0304-9 – ident: ref26 doi: 10.3389/fphar.2017.00561 – start-page: 317A volume-title: Characterization of the surface expression of PD-1/PD-L1 signaling proteins in high-grade serous ovarian carcinoma year: 2017 ident: ref36 – ident: ref13 doi: 10.1016/j.ygyno.2018.08.023 – ident: ref4 doi: 10.1038/nrc3239 – ident: ref20 doi: 10.1126/scitranslmed.3003689 – ident: ref27 doi: 10.5858/arpa.2016-0361-RA – ident: ref15 doi: 10.1093/annonc/mdw625 – ident: ref3 doi: 10.1016/j.celrep.2017.07.075 – ident: ref1 doi: 10.3322/caac.21262 – ident: ref9 doi: 10.3802/jgo.2017.28.e77 – ident: ref21 doi: 10.1073/pnas.0406351101 – ident: ref33 doi: 10.1016/j.cell.2015.08.052 – ident: ref23 doi: 10.1038/bjc.2015.101 – ident: ref5 doi: 10.1073/pnas.0611533104 – ident: ref12 doi: 10.1097/PGP.0000000000000494 – ident: ref28 doi: 10.1016/j.lungcan.2016.05.001 – ident: ref32 doi: 10.1186/s13048-018-0414-z – ident: ref31 doi: 10.1038/modpathol.2016.221 – ident: ref30 doi: 10.4143/crt.2016.066 – ident: ref18 doi: 10.1126/scitranslmed.aad7118 – ident: ref34 doi: 10.1007/s10147-016-0968-y – ident: ref10 doi: 10.1016/j.ygyno.2016.03.008 – ident: ref17 doi: 10.1155/2018/9485285 |
| SSID | ssj0000851884 |
| Score | 2.1746562 |
| Snippet | To investigate the prognostic significance of programmed cell death ligand-1 (PD-L1) in ovarian cancer.
PubMed, Embase, and Cochrane Library databases were... To investigate the prognostic significance of programmed cell death ligand-1 (PD-L1) in ovarian cancer.OBJECTIVETo investigate the prognostic significance of... ObjectiveTo investigate the prognostic significance of programmed cell death ligand-1 (PD-L1) in ovarian cancer.MethodsPubMed, Embase, and Cochrane Library... ObjectiveTo investigate the prognostic significance of programmed cell death ligand-1 (PD-L1) in ovarian cancer. MethodsPubMed, Embase, and Cochrane Library... |
| SourceID | nrf doaj pubmedcentral proquest pubmed crossref |
| SourceType | Open Website Open Access Repository Aggregation Database Index Database Enrichment Source |
| StartPage | 346 |
| SubjectTerms | Original ovarian cancer pd-l1 prognosis progression-free survival survival rate 산부인과학 |
| SummonAdditionalLinks | – databaseName: DOAJ : Directory of Open Access Journals [open access] dbid: DOA link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Lb9QwELZQD4gL4s3ykkGckNw6tuM43ABRFSQQByr1ZvmVJW1xqmi36s9nxklXuwjBBeWwq8ROZj0Tz_cls58Jea29aUzUiXXKKKZcVTEv2sTKvx69cYC4i9rnV310rD6f1CdbS31hTdgkDzwN3EGohXHcaW68URHgjAgNJBU4R-e1aj3OvrzlW2TqdKq-qkxZblgAJWCmbsT0SrNW2hwMSxTqFnxfy33YEPxuJaWi3Q-pJo_dn2Dn79WTW-no8A65PeNI-m6y_y65kfI9cvPL_Kb8Pum_jQPW0MFhioLeiQ4dnYux4KwUH9jTiPiPnvdLlyOraLqaq2Iz7TMdLoFGu0wDxsX4lsLX9QU-H4j0Z1o55mY5kwfk-PDj9w9HbF5WgQWgNysWW2CFWkSsT6sVZHCYtKoUZS15ciLVAJG4NF1MnkfDvUpN7V2ngxddE0JI8iHZy0NOjwlYoKCBji5Cp-Ijzb2OANir2GmpF4Rfj6sNs-Y4Ln1xboF7oCssuMKiK6yWFjYFXd5sulxMght_a_wenbVpiFrZZQdEkJ0jyP4rghbkFbjanoW-9MfP5WDPRguM4pNtUdDewJVeXkeChRsQneRyGtZgEDBkQFVSyAV5NEXGxh5Aq8hn-YI0OzGzY_Dukdz_KCLfDQBvgI5P_scvfEpu4bBNdZrPyN5qXKfngKVW_kW5bX4BcuAYxw priority: 102 providerName: Directory of Open Access Journals |
| Title | Prognostic value of programmed cell death ligand-1 expression in ovarian cancer: an updated meta-analysis |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/32489980 https://www.proquest.com/docview/2409190323 https://pubmed.ncbi.nlm.nih.gov/PMC7231937 https://doaj.org/article/c528a0a608b84d9992c7266259fb649b https://www.kci.go.kr/kciportal/ci/sereArticleSearch/ciSereArtiView.kci?sereArticleSearchBean.artiId=ART002586939 |
| Volume | 63 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| ispartofPNX | Obstetrics & Gynecology Science, 2020, 63(3), 651, pp.346-356 |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV3fb9MwELbGkBAviN90wGQQT0guTuI4Li8IENNAGuKBSnuz_CtdWXG20KLx33PnuBVFFUJ5aJXYycl3rr_PuX5HyAtpVaO8DKwVSjBhioLZchJY-tejVQYQd1L7_CyPp-LTaX26R9blrfIA_thJ7bCe1LRfjK8uf72BCQ_4dVwLqV51M9TdLvlYVmM4hLxGrsPCJJGLnWS0_21IySpUqkFcAk9gqm7K4T3n7rtsrVRJ0B_Wn9i3u7Do3ymVf6xRR7fJrQwu6dshGu6QvRDvkhsn-fX5PTL_0neYWAeXKap8B9q1NGdowV0p7uJTj6CQLuYzEz0raLjKqbKRziPtfgK3NpE6DJb-NYWvqwvcNPD0e1gaZrLGyX0yPfrw9f0xy7UWmAPOs2R-AlRRlh6T1moBowe_ZEXwVV3xYMpQA27ilWp9sNwrbkVoamta6WzZNs65UD0g-7GL4REBCwQ0kN546GQkV1ZyKz2g-MK3spIjwtfjql0WIsd6GAsNhARdocEVGl2hZaXhENDl5abLxaDC8a_G79BZm4YooJ1OdP1M5_moXV0qw5N1SnhAyaVrAKtAaLZWiokdkefgan3u5qk_fs46fd5roBkf9QRV7hU86dk6EjTMSnSSiaFbgUFAmwFqVWU1Ig-HyNjYAxAWSS4fkWYrZrYM3r4S52dJ-bsBNA548uA_nvuY3MRRGXIzn5D9Zb8KTwE_Le1h2nc4THPjN7X_F4s |
| linkProvider | Scholars Portal |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Prognostic+value+of+programmed+cell+death+ligand-1+expression+in+ovarian+cancer%3A+an+updated+meta-analysis&rft.jtitle=Obstetrics+%26+gynecology+science&rft.au=Piao%2C+Jinlan&rft.au=Lim%2C+Hyun+Ji&rft.au=Lee%2C+Maria&rft.date=2020-05-01&rft.issn=2287-8572&rft.volume=63&rft.issue=3&rft.spage=346&rft_id=info:doi/10.5468%2Fogs.2020.63.3.346&rft.externalDBID=NO_FULL_TEXT |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2287-8572&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2287-8572&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2287-8572&client=summon |